Answers are grounded in this paper and cite their sources.
The safety and efficacy of axi-cel in the SOC setting in patients with relapsed/refractory LBCL was comparable to the registrational ZUMA-1 trial.
No takes yet. Share an insight, caveat, or question.
Nastoupil et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: